Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne muscular dystrophy is caused by mutations in the dystrophin gene resulting in the loss of the dystrophin glycoprotein complex in skeletal muscle Loss of dystrophin results in reduced sarcolemmal integrity progressive muscle damage and compromised muscle function There is currently no cure and limited treatment options for DMD and all affected child ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION provided by applicant The number of Lyme disease cases in the US has been recently estimated by the CDC at cases year This is major public health concern Currently available diagnostics rely on detection of the antibody response serology to Borrelia burgdorferi the causative agent of Lyme disease However serological tests are not accurate during the early stages of Ly ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Electro-Mechanical Micro-Post Array to Detect In Vitro Muscle Contraction

    SBC: MYOMICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Myomics? technology to be developed in this Phase 1 project is based upon an in vitro skeletal muscle tissue force measurement technique for high throughput screening (HTS) of compounds to attenuate muscle weakness. The technology, termed Patterned Micro-Post-Arrays (P-fPA), is comprised of bioengineered skeletal muscle tissue attached to micro-mechanical senso ...

    STTR Phase I 2006 Department of Health and Human Services
  5. Role of Inter-alpha Inhibitors in Anthrax Intoxication

    SBC: PROTHERA BIOLOGICS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor proteins (lalp) as an effective protective agent against exposure to anthrax, a lethal biological warfare agent. Inter-alpha inhibitor proteins are natural serine protease inhibitors found in relatively high concentration in human plasma. The protein complex h ...

    STTR Phase I 2006 Department of Health and Human Services
US Flag An Official Website of the United States Government